Cargando…

Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review

With the development of immunotherapy, immune checkpoint inhibitors (ICIs) are widely used in clinical oncology and have achieved good results. ICIs could induce immune-related adverse events (irAEs) in cancer treatment, which warrant sufficient attention. Among them, immune myositis can manifest se...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Haoran, Wen, Wu, Fang, Kang, Xiong, Yuanpeng, Liu, Weiqi, Wang, Jie, Wan, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876740/
https://www.ncbi.nlm.nih.gov/pubmed/36713559
http://dx.doi.org/10.3389/fonc.2022.1088659
_version_ 1784878229198209024
author Mei, Haoran
Wen, Wu
Fang, Kang
Xiong, Yuanpeng
Liu, Weiqi
Wang, Jie
Wan, Renhua
author_facet Mei, Haoran
Wen, Wu
Fang, Kang
Xiong, Yuanpeng
Liu, Weiqi
Wang, Jie
Wan, Renhua
author_sort Mei, Haoran
collection PubMed
description With the development of immunotherapy, immune checkpoint inhibitors (ICIs) are widely used in clinical oncology and have achieved good results. ICIs could induce immune-related adverse events (irAEs) in cancer treatment, which warrant sufficient attention. Among them, immune myositis can manifest severe symptoms affecting the whole body, and immune myocarditis occurs with a low incidence but high fatality rate. Here we report a case of grade 3/4 adverse reactions in a patient with partial hepatectomy for malignancy after using ICIs and describe the clinical presentation, laboratory results, treatment, and prognosis. It emphasizes that clinicians should focus on being alert to irAEs in liver cancer patients who have received ICI therapy. The case we present is a 56-year-old male diagnosed with hepatocellular carcinoma. Right hepatic lobectomy was performed in April 2019. Postoperative follow-up showed that transcatheter arterial chemoembolization (TACE) combined with sorafenib (400 mg twice daily) failed to stop the recurrence of the tumor. In December 2020, the patient started to use Camrelizumab injections (200mg/injection every 21 days as a cycle). After 3 cycles, the patient had decreased muscle strength in both lower extremities with chest tightness, dyspnea, and expectoration (whitish sputum). The diagnosis was ICIs injection-induced immune myocarditis and myositis accompanied. The patient’s condition improved considerably by steroid pulse therapy timely. The case emphasizes that clinicians should focus on being alert to irAEs in liver cancer patients who have received ICI therapy.
format Online
Article
Text
id pubmed-9876740
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98767402023-01-26 Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review Mei, Haoran Wen, Wu Fang, Kang Xiong, Yuanpeng Liu, Weiqi Wang, Jie Wan, Renhua Front Oncol Oncology With the development of immunotherapy, immune checkpoint inhibitors (ICIs) are widely used in clinical oncology and have achieved good results. ICIs could induce immune-related adverse events (irAEs) in cancer treatment, which warrant sufficient attention. Among them, immune myositis can manifest severe symptoms affecting the whole body, and immune myocarditis occurs with a low incidence but high fatality rate. Here we report a case of grade 3/4 adverse reactions in a patient with partial hepatectomy for malignancy after using ICIs and describe the clinical presentation, laboratory results, treatment, and prognosis. It emphasizes that clinicians should focus on being alert to irAEs in liver cancer patients who have received ICI therapy. The case we present is a 56-year-old male diagnosed with hepatocellular carcinoma. Right hepatic lobectomy was performed in April 2019. Postoperative follow-up showed that transcatheter arterial chemoembolization (TACE) combined with sorafenib (400 mg twice daily) failed to stop the recurrence of the tumor. In December 2020, the patient started to use Camrelizumab injections (200mg/injection every 21 days as a cycle). After 3 cycles, the patient had decreased muscle strength in both lower extremities with chest tightness, dyspnea, and expectoration (whitish sputum). The diagnosis was ICIs injection-induced immune myocarditis and myositis accompanied. The patient’s condition improved considerably by steroid pulse therapy timely. The case emphasizes that clinicians should focus on being alert to irAEs in liver cancer patients who have received ICI therapy. Frontiers Media S.A. 2023-01-11 /pmc/articles/PMC9876740/ /pubmed/36713559 http://dx.doi.org/10.3389/fonc.2022.1088659 Text en Copyright © 2023 Mei, Wen, Fang, Xiong, Liu, Wang and Wan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Mei, Haoran
Wen, Wu
Fang, Kang
Xiong, Yuanpeng
Liu, Weiqi
Wang, Jie
Wan, Renhua
Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review
title Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review
title_full Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review
title_fullStr Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review
title_full_unstemmed Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review
title_short Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review
title_sort immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: a case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876740/
https://www.ncbi.nlm.nih.gov/pubmed/36713559
http://dx.doi.org/10.3389/fonc.2022.1088659
work_keys_str_mv AT meihaoran immunecheckpointinhibitorinducedmyocarditisandmyositisinlivercancerpatientsacasereportandliteraturereview
AT wenwu immunecheckpointinhibitorinducedmyocarditisandmyositisinlivercancerpatientsacasereportandliteraturereview
AT fangkang immunecheckpointinhibitorinducedmyocarditisandmyositisinlivercancerpatientsacasereportandliteraturereview
AT xiongyuanpeng immunecheckpointinhibitorinducedmyocarditisandmyositisinlivercancerpatientsacasereportandliteraturereview
AT liuweiqi immunecheckpointinhibitorinducedmyocarditisandmyositisinlivercancerpatientsacasereportandliteraturereview
AT wangjie immunecheckpointinhibitorinducedmyocarditisandmyositisinlivercancerpatientsacasereportandliteraturereview
AT wanrenhua immunecheckpointinhibitorinducedmyocarditisandmyositisinlivercancerpatientsacasereportandliteraturereview